1. Data of the interim analysis of the GPOH-HD2002 pilot study support that COPDAC is an effective and safe treatment option. Relevant safety information is updated. 2. Treatment of study patients who refuse randomisation. (In the event of refusal of randomisation between COPP and COPDAC the recommendation of the trial chairpersons is that COPP is considered as the standard arm. In these situations these patients will remain on the study. These patients will be informative concerning the STAR question and add to the safety data. Patients should not be treated on the COPDAC arm outside the study.) 3. SAE reporting: Time horizon and clarification in order avoid unnecessary SAE – reporting. (SAE reporting is restricted to events occurring within 3 month after the end of the study treatment; addition of expected toxicities for each IMP and RT) 4. Administrative data (update of contact data, correction of typos)

1. Clarification of discrepancies between patient information and informed consent declaration concerning time of archiving 2. Change of members in the central review team and in the panel of referenpathologists. 3. Title of patient information and informed consent for relapse treatment is adjusted to the protocol. The inclusion criteria do not contain an age limit for patients with relapse of childhood and adolescent Hodgkin`s Lymphoma 4. Clarification in patient information for primary and relapse treatment that depending on the treatment center either prednisone or prednisolon will be used as prescribed in the final version of the treatment protocol 5. Clarification of antibacterial prophylaxis since the use of these drugs is differently handled in the various countries and institutions. However, this will not affect the study results, since all patients will receive a necessary prophylaxis. 6. The protocol prescribes either Prednisone or Prednisolone. In the abbreviation section only prednisone was listed, Therefore prednisolone was added for formal correctness. 7. Administrative data (update of contact data)

1. Stop randomisation COPP vs COPDAC: Further to a Clinical Board Meeting of EuroNet-PHL and the Annual EuroNet-PHL Clinicians Meeting (from 09.02.2012 to 11.02.2012), a decision was made to end the randomisation between COPP and COPDAC for eligible Patients in the EuroNet-PHL-C1 trial. This decision was made on the basis of the results of the second interim data analysis which showed emerging evidence that COPP and COPDAC are similarly efficacious. In view of the evidence that emerged from the interim data analysis of EuroNet PHL-C1 the Clinical Board and associated parties saw a change in the risk-benefit assessment for the trial and decided that randomisation should be stopped on 13.02.2012. Although the data was immature, it was clear that the sample size was sufficient to answer the randomised question on efficacy and that furthermore it was essential to avoid the potentially detrimental effects of COPP on male fertility. All Patients in EuroNet-PHL-C1 (in TG-2 and TG-3) should now receive COPDAC. The trial remained open to recruitment (outside of Germany) because that data was required to fully answer the other important questions in the protocol relating to the STAR approach to treatment and whether it is safe to omit radiotherapy. 2. Administrative data: Update of contact data

1. Addition of global scientific side projects: a) DETERMINATION OF ANTI MULLERIAN AND OTHER GONADAL HORMONES IN FEMALE PATIENTS OF THE EURONET-PHL-C1 PATIENTS; b) QUALITY CONTROL IN RADIOTHERAPY; c) INCIDENCE OF OSTEONECROSES IN CHILDREN AND ADOLESCENTS TREATED WITHIN THE EURONET-PHL-C1 TRIAL 2. Addition of country-specific scientific side projects: a) IDENTIFICATION OF A PROGNOSTIC GENE EXPRESSION SIGNATURE IN PEDIATRIC HODGKIN’S LYMPHOMA IN CONTEXT OF THE EURONET-PHL-C1 TRIAL; b) IDENTIFICATION OF DISTINCTIVE PATHOLOGIC FEATURES OF PEDIATRIC HODGKIN’S LYMPHOMAS WITH ABNORMAL CHEMO RESPONSE IN CONTEXT OF THE EURONET-PHL-C1 TRIAL c) ASSESSMENT OF LATE EFFECTS IN PATIENTS TREATED ACCORDING TO EURONET-PHL-C1